Login to Your Account

Oxford BioMedica Encouraged By Early Gene Therapy Studies

By Nuala Moran

Wednesday, February 27, 2002
LONDON - Oxford BioMedica plc said it achieved positive interim results from Phase I/II trials of MetXia and TroVax, showing the two cancer gene therapy products were safe and prompted clinical improvements in several of those treated. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription